Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy

Medical Oncology

Volumn 23, Issue 1, 2006, Pages 121-124

  Grubisic Cabo F ^a   Vrdoljak, E ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Adjuvant therapy; Gemfibrozil; Hepatitis; Interferon alfa; Side effects

Indexed keywords

ALPHA2B INTERFERON; ELMOGAN; GEMFIBROZIL; RECOMBINANT ALPHA2B INTERFERON; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; FEMALE; HUMAN; HYPERLIPIDEMIA; LABORATORY TEST; MALAISE; MELANOMA; NAUSEA; PRESCRIPTION; PRIORITY JOURNAL; TOXIC HEPATITIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; FEMALE; GEMFIBROZIL; HEPATITIS, TOXIC; HUMANS; INTERFERON ALFA-2B; MELANOMA; MIDDLE AGED;

EID: 33646896518     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:1:121     Document Type: Article

References (19)

1. Lotze MT, Dallai RM, Kirkwood JM, Flickinger JC. Cutaneous melanoma. In: De Vita V, Hellmann S, Rosenberg SA. (eds). Cancer - principles and practice of oncology, 6th ed., Lippincott Williams & Wilkins, Philadelphia, PA, 2001, pp. 2012-2069.
2. Lancaster HO. Some geographical aspects of the mortality from melanoma in Eur Med J Aust 1956; 1: 1082.
3. Titus-Ernstoff L, et al. Factors associated with atypical nevi: a population-based study. Cancer Epidemiol Biomarkers Prev 1998; 7: 207.
4. Karjalainen S, Hakulinen T. Survival and prognostic factors of patients with skin melanomas. Cancer 1988; 62: 2274.
5. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993; 71: 2995.
6. Hancock BW, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22(1): 53.
7. Kirkwood JM, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7.
8. Kirkwood JM, et al. Preliminary analysis of the E 1690/S9111/ C 9190 Intergroup postoperative adjuvant trail of high and low dose IFN alfa-2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma. Proc Am Soc Clin Oncol 1999; 18: 537.
9. Kirkwood JM, et al. Mechanism and management of toxocities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20(17): 3703.
10. Wong SF, Jakowatz JG, Taheri R. Managament of hypertrigliceridemia in patients receiving interferon for malignant melanoma. Ann Pharmacother 2004; 38(10): 1655.
11. Rabasa-Lhoret R, Rasamisoa M, Avignon A, Monnier L. Rare side-effects of fenofibrate. Diabetes Metab 2001; 27(1): 66.
12. Berruti A, et al. Hypertrigliceridemia during long-term interferon alpha therapy - efficacy of diet and gemfibrozil treatment. A case report. Tumori 1992; 78(5): 353.
13. Rubins HB, et al. Intervention trial study group. N Engl J Med 1999; 341: 410.
14. Lopid product information (Parke-Davis-Canada), Rev 11/88, Rec 4/89.
15. Bustamante Balen M, Plume Gimeno G, Bau Gonzales I, Berenguer Lapuerta J. Acute hepatitis caused by gemfibrozil. Gastroenterol Hepatol 1998; 21(8): 419.
16. Amacher DE, Beck R, Schomaker SJ, Kenny CV. Hepatic microsomial enzyme induction, B-oxidation and cell proliferation following administration of clofibrate, gemfibrozil or bezafibrate in CD rat. Toxil Appl Pharmacol 1997; 142: 143.
17. Hashimoto F, Ishikawa T, Hamada S, Hayashi H. Effect of gemfibrozil on lipid biosynthesis from acetyl-CoA derived from peroxismal β-oxidation. Biochem Pharmacol 1995; 49: 1213.
18. Hendriks F, Kooman JP, van der Sande FM. Massive rhabdomiolysis and life threatening hyperkaliemia in a patient with the combination of cerivastatin and gemfibrozil. Nephrol Dial Transplant 2001; 16(12): 2418.
19. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437.